cortisol
(2)
Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing clofutriben, an oral, once-daily HSD-1 inhibitor that lowers active cortisol inside specific tissues rather than shutting down the body's steroid system entirely. Founded in 2013 by scientist David Katz, the company has raised roughly $145 million across Series A and Series B rounds and is running the Phase 2b CAPTAIN-T2D trial in patients with type 2 diabetes and elevated cortisol, alongside programs in Cushing's syndrome and autonomous cortisol secretion.
Rarebird, Inc.
Rarebird is a New York and San Leandro-based specialty coffee company that replaces caffeine with paraxanthine (Px), the natural metabolite your body turns caffeine into. Founded by bioengineer Dr. Jeffrey Dietrich, Rarebird uses a patented reverse-infusion process to load 60mg of Px into single-origin Colombian decaf beans, promising alertness and focus without the jitters, anxiety, cortisol spikes, or wrecked sleep. Backed by Y Combinator, AgFunder, First Round Capital and the National Science Foundation, Rarebird is trying to make Px 'the third coffee' - a category alongside regular and decaf.